You are here

P&T® Journal contents for January 2009

Features

Opinion
With the recession affecting everyone’s wallets, many people are forgoing some basic needs and rethinking their priorities. Instead of opting for expensive, ­aggressive therapies, for example, some cancer patients are deciding against ­lifesaving treatment. This shift in thinking is sure to have a significant effect on ­physicians, insurance companies, employers, and the patients themselves.
F. Randy Vogenberg, RPh, PhD, and Stephen Cutts, PharmD Candidate
Topics include fesoterodine fumarate extended-release tablets (Toviaz) for patients with overactive bladder; rufinamide (Banzel) as an adjunctive therapy for seizures associated with Lennox–Gastaut syndrome; and eltrombopag (Promacta) to treat thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Some of the topics covered at the AHA sessions included therapies for acute coronary syndromes, C-reactive protein levels, and familial hypercholesterolemia. NSAID-related GI events, presented at the European meeting, are still a significant concern. News on the radiology front featured golimumab for patients with psoriatic arthritis, tocilizumab for rheumatoid arthritis, and infliximab (Remicade) plus methotrexate, also for rheumatoid arthritis.
Walter Alexander
Continuing Education Credit
Rosacea, a common inflammatory condition of the facial skin, affects between 0.5% and 10% of the population. The authors review the wide array of available FDA-approved and non–FDA-approved treatment options and emphasize the importance of the pharmacist’s role in prescribing appropriate medications for the various presentations of this dermatological ailment.
Brittney Culp, BA, and Noah Scheinfeld, MD
Commentary
With a new administration in place, pharmacists may play a larger advisory role.
Stephen Barlas
The AURA tool enables health plans to evaluate quality and use of resources for their members with asthma by analyzing medical and pharmacy claims.
James H. Jackson, PharmD, MPH; Benjamin Gutierrez, PhD; Orsolya E. Lunacsek, PhD, MBA; and Sulabha Ramachandran, PhD
Products include fospropofol for se­dation; plerixafor to prepare patients for transplantation; and fenofibric acid for improving triglycerides and cholesterol.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
The authors report on a project to sequence the genomes of more than 1,000 people; Gaucher’s disease; warfarin genetics; and Huntington’s disease.
Safiya Abouzaid, PharmD; Joseph E. Couto, PharmD, MBA; and Marc B. Royo
Meeting Highlights
Topics include leukemias, myelodysplastic disorder, multiple myeloma, paroxysmal nocturnal hemoglobinuria, and idiopathic thrombocytopenic purpura.
Walter Alexander
Meeting Highlights
Summaries discuss zoledronic acid, everolimus, lapatinib, and letrozole.
Walter Alexander
Book Review
Third edition of a classic psychopharmacology text
Reviewed by David A. Casey, MD
Patients who need enteral nutrition may also require PPIs for acid suppression. The currently available and most widely prescribed PPIs are reviewed, along with their routes of delivery in nasogastric, gastrostomy, and jejunal feeding tubes.
Terri M. Wensel, PharmD
Commentary
Emerging Trends in the Blogosphere
Even pharmaceutical companies, which have long shied away from blogging on the Internet, understand that the conventional static Web site is just not good enough any more. Will future pharma bloggers be able to incorporate the real-time engagement and transparency that are needed?
Miriam Reisman
Meeting Highlights
If approved by the FDA, the platelet inhibitor prasugrel will be a first-in-its-class competitor of clopidogrel (Plavix). The new drug is designed to reduce the risk of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular disease, but bleeding and the risk of neoplasms can result.
Walter Alexander
Topics include milnacipran (Savella) tablets for fibromyalgia, calcitriol ointment (Vectical) for plaque psoriasis, and degarelix subcutaneous injection, a hormone for treating advanced prostate cancer.
Marvin M. Goldenberg, PhD, RPh, MS
Health Care & Law
Information about physician behavior, including malpractice judgments, is becoming more public now, especially on the Internet, and many health care professionals are concerned about Web-based patient critiques. Two court cases show that although physician privacy has prevailed, it is expected to face ongoing challenges.
Robert I. Field, JD, MPH, PhD
In a retrospective study, 100 mg of micafungin given once daily was as cost-effective as the 150-mg dose and yielded significant savings of $300 per patient.
Kwaku Marfo, PharmD, BCPS, and Yi Guo, PharmD
Topics include febuxostat (Uloric) in managing excess uric acid in gout; Hylan G-F 20 (Synvisc-One) for treating pain in osteoarthritis; and fibrinogen concentrate (RiaSTAP), an orphan drug to treat acute bleeding in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
Cancer and Chronic Lyme Disease
Discussions include supplements and herbs for breast cancer; chemoprotectant ribosomal RNA for advanced cancer; and conventional drugs with complementary therapies for patients with Lyme disease and other tick-borne disorders.
Walter Alexander
Continuing Education Credit
A Review of Treatment Options
Spontaneous bacterial peritonitis (SBP) often affects patients with cirrhosis and ascites. The authors review the pathogenesis and diagnosis of SBP, differentiate between primary SBP and secondary peritonitis, and discuss current therapies.
Cesar Alaniz, PharmD, and Randolph E. Regal, PharmD

Departments

Editorial
David B. Nash, MD, MBA, has found gold: a source of cutting-edge online CME ­lectures not funded by the pharmaceutical industry.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, discusses how process, structure, outcome, and balance measures can help protect hospitalized patients from adverse drug events.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the challenges of implementing a national drug-tracking law.
Stephen Barlas
From Boostrix to tapentadol, P&T presents the latest studies and information about FDA approvals, new indications, recalls, and industry updates.
Editorial
David B. Nash, MD, MBA, describes the goals of the National Quality Forum in improving health care in six key areas as well as eliminating unnecessary services.
David B. Nash, MD, MBA
Medication Errors
Is Glacial Acetic Acid Really Needed?
Matthew Grissinger, RPh, FASCP, explains how patients can be harmed when glacial (pure) acetic acid, instead of a diluted form, is dispensed.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the long-simmering debate over the content of consumer medication information.
Stephen Barlas
From Mozobil to Zolpimist, P&T presents the latest studies and information about FDA approvals, new indications, recalls, and industry updates.
Drug Forecast
Hoyee Leong, PhD, and Mary Ellen Bonk, PharmD, review bendamustine (Treanda), a therapy for chronic lymphocytic leukemia.
Hoyee Leong, PhD, and Mary Ellen Bonk, PharmD
Editorial
David B. Nash, MD, MBA, discusses evidence-based case rates, the building blocks of a new payment model that aims to support a patient-centered health environment.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, recommends rest periods, off-duty time, naps, meal breaks, and other safety practices to prevent fatigue in health care workers, thereby minimizing the potential for mistakes on the job.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses how the FDA under the Obama administration might deal with off-label drug promotion for unapproved uses.
Stephen Barlas
From ATryn to Tindamax, P&T presents the latest information about FDA approvals, indications, recalls, and updates.
Drug Forecast
Drs. Kapur and Bonk review rilonacept (Arcalyst) for treating cryopyrin-associated periodic syndromes.
Saloni Kapur, PharmD, MPA, and Mary Ellen Bonk, PharmD
Editorial
Although skeptics say fixing Big Pharma is not possible, David B. Nash, MD, MBA, describes a “cultural revolution” in which small elite groups within centers of excellence could revitalize R&D.
David B. Nash, MD, MBA